News

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

Arrowhead's ARO-DIMER-PA cut PCSK9 by 72% and APOC3 by 88% with single doses, driving LDL-C and triglyceride reductions in mixed hyperlipidemia.

FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.

Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for a patient with psoriatic arthritis.

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.

David Oberlin, MD, explains why APEX's enriched trial population, not drug mechanism, likely drove its unique radiographic success in psoriatic arthritis.

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

Luke Laffin, MD, discusses his secondary analysis of the phase 2 KARDINAL trial, which demonstrated substantial improvements in uncontrolled hypertension.

Wechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.

Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.

Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.

The novel cardiac sarcomere modulator from Edgewise Therapeutics saw substantial improvements in both nonobstructive and obstructive HCM after 12 weeks.

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

Guy Brusselle, MD, PhD, explains why broader cytokine blockade with dupilumab outpaced omalizumab, and why nonremitters in EVEREST still improved.

Adam Friedman, MD, breaks down how to say no strategically in dermatology, from delaying an answer to sharing the decision with the requester.

As ragweed and mold drive this year's fall symptom surge, updated GRADE recommendations shift first-line therapy toward combination intranasal treatment.

Stay updated with the latest healthcare breakthroughs, including a new ablation catheter for AFib and progress in the hereditary angioedema pipeline.

Robert Giugliano, MD, breaks down his prespecified subanalysis of the VESALIUS-CV trial, evaluating evolocumab’s effect on cardiovascular mortality.

Phase 2 VALIANT data show the anti-TSLP receptor antibody sharply reduced exacerbations in patients with high eosinophil counts.

Kristina Duffin, MD, dean of the Spencer Fox Eccles School of Medicine, discusses leadership, delegation, and coaching at LEADderm 2026.

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

Sadiya Khan, MD, MSc, discusses the session she chaired at ESC 2026, which saw clinicians discuss the equitability of artificial intelligence in medicine.

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Mohammad Ali Salehinejad, PhD, explains how template-based targeting could extend optimized multichannel tDCS to broader clinical and home-based care.

Oyvind Lie, MD, PhD, MSc, discusses the results from the ACASA-TAVI trial, which sought to evaluate the efficacy of anticoagulant monotherapy in this population.

Peter Lio, MD, breaks down AdvanceAD-Tx testing and oral STAT6 degrader KT-621 in the atopic dermatitis pipeline.